31st May 2018 07:00
TOTAL VOTING RIGHTS
VERNALIS PLC (the "Company")
31 May 2018
Vernalis plc (LSE: VER) announces that the Company's total issued share capital at the date of this announcement is 526,830,515 ordinary shares of 1p each, with one voting right per share. There are no shares held in treasury.
The total number of voting rights in the Company is therefore 526,830,515.
The above figure of 526,830,515 shares may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company.
- ends -
Enquiries:
Vernalis plc: | +44 (0) 118 938 0015 |
Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer
| |
Canaccord plc (Nominated Adviser and Joint Broker): | +44 (0) 20 7523 8000 |
Henry Fitzgerald-O'Connor Emma Gabriel
| |
Shore Capital (Joint Broker): | +44 (0)20 7408 4090 |
Mark Percy Toby Gibbs
| |
FTI Consulting (Financial Communications): | +44 (0) 20 3727 1000 |
Ben Atwell Simon Conway Stephanie Cuthbert
| |
Evercore (Financial Adviser): | +44 (0) 20 7653 6000 |
Julian Oakley Alan Beirne
|
Notes to Editors
About Vernalis
Vernalis is a revenue generating, pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra® XR targeting the US prescription cough-cold market; Moxatag®, a once-daily formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. Vernalis has also nine programmes in its NCE development pipeline in addition to significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Daiichi Sankyo, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.
For further information about Vernalis, please visit www.vernalis.com
Related Shares:
Vernalis PLC